PROMPT SEPSIS : Partnership for Rapid On-site Microfluidic POC Test for Sepsis

PROMPT SEPSIS：脓毒症快速现场微流控 POC 测试合作伙伴

• 批准号: EP/K503630/1
• 负责人: Enitan Carrol
• 金额: $ 20.21万
• 依托单位: University of Liverpool
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FK503630%2F1
• 关键词: PROMPT; SEPSIS; Partnership; Rapid; site

The University of Liverpool (UoL) has identified a combination of 3 biomarkers which provide good discrimination of sepsisin febrile children. MicroLab Devices (MLD), Forsite Diagnostics (FD) and UoL have combined their technology to developan innovative point-of-care (POC) diagnostic system combining microfluidic and lateral flow technology to provide adisposable, zero energy platform for measuring this combination of sepsis markers. The project will refine the POC systemfor the introduction of raw saliva or blood samples directly into the system and validate the device using clinical samples tocreate a diagnostic algorithm to guide decision making. The innovation lies in the novel combination of biomarkers AND thecombined platform technologies that provide a new diagnostic system to allow the detection of sepsis rapidly and cheaply.The test has the potential to reduce delays in diagnosis and unnecessary admissions to hospital and the platform has thepotential to impact across the whole POC market.

利物浦大学(UOL)已经确定了3种生物标志物的组合，它们可以很好地区分发烧儿童的败血症。MicroLab Devices(MLD)、Forsite Diagnostics(FD)和UOL将他们的技术结合在一起开发了一种创新的护理点(POC)诊断系统，该系统结合了微流控和侧向流动技术，为检测这两种败血症标志物的组合提供了可拆卸的零能量平台。该项目将改进POC系统，将原始唾液或血液样本直接引入该系统，并使用临床样本验证该设备，以创建指导决策的诊断算法。创新之处在于生物标志物和组合平台技术的新颖组合，提供了一种新的诊断系统，允许快速且廉价地检测脓毒症。检测具有减少诊断延误和不必要的入院的潜力，该平台具有影响整个POC市场的潜力。